StroMedix Lands $25,000,000 Series B Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=878417c0-b377-49b0-836e-746a93aab797&Preview=1 -
Date
4/21/2008 -
Company Name
StroMedix -
Mailing Address
One Canal Park Cambridge, MA 02142 -
Company Description
Stromedix is a clinical-stage biotechnology company committed to developing novel drugs to treat fibrotic organ failure. Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer. The company plans to build its pipeline through both internal drug discovery and in-licensing. -
Website
http://www.stromedix.com -
Transaction Type
Venture Equity -
Transaction Amount
$25,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Earlier this year, Stromedix initiated a Phase 1 clinical trial of STX-100, the Company’s lead drug candidate. STX-100 is a novel humanized monoclonal antibody licensed in 2007 from Biogen Idec, which is also a shareholder in the company. -
M&A Terms
-
Venture Investor
New Leaf Venture Partners -
Venture Investor
Bessemer Venture Partners -
Venture Investor
Red Abbey Venture Partners -
Venture Investor
Atlas Venture -
Venture Investor
Frazier Healthcare Ventures
